Chelsea Therapeutics International Ltd (NASDAQ:CHTP) Given Another Chance of Proving Northera

Stamford, CT -- (SBWIRE) -- 02/20/2013 -- Jet Life Penny Stocks provides investors with the Awesome Penny Stock alerts on a regular basis. We will send you alerts through our Penny Stock Newsletters and offer you the tools to help you along the way with the goal of keeping you loyal to our service.

Chelsea Therapeutics International Ltd (NASDAQ:CHTP) reported that US health controllers have told the firm that it might reapply for the marketing acceptance of its once-refused hypotension drug Northera using data from its previous study.

Chelsea's stock has surged more than twofold in worth to $1.61 ahead of the bell on Wednesday, as the firm reported that it intends to file for acceptance for the drug in the second quarter of the year.

What does FDA has asked Chelsea Therapeutics about the matter? Find out here

The US Food and Drug Administration had refused Northera previous March and told Chelsea (CHTP) to carry on another clinical trial to prove that the drug was effective over an extended period.

We now possess a regulatory path ahead, counting the possibility for an acceptance of Northera afterward this year, Chelsea's interim Chief Executive Joseph Oliveto articulated.

FDA's outlook was in reaction to a formal petition by Chelsea to the Director of the Office of New Drugs of the FDA, Chelsea reported in a statement.

The firm (CHTP) reported that it intends to begin a new clinical experiment in the Q4 of the year to check for long-term advantages of the drug.

NetSpend Holdings (NASDAQ:NTSP) has decided to be bought by Total System Services in a bid of $1.4 billion, or $16 per share. NTSP, which ended lower at $12.29 on Tuesday, was higher 28.72% percent dring regular trading session on Wednesday.

How analysts aimed towards NetSpend stock? Find out in this report

After the deal was announced NetSpend (NTSP) was lowered to Neutral rating from Outperform at Credit Suisse.

About Jetlifepennystock.com
Jet Life Penny Stocks is always searching the market every day for massive penny stock runs before they happen so you don't have to. Jet Life Penny Stocks also offers free Highly-Professional Grade stock charts and video charts from one of the most experienced and well-respected chartists in the penny stock industry.

Disclaimer
Jet Life Penny Stocks is not a registered securities advisor. Investors should always conduct their own additional due diligence with any potential investment or highlighted company. The company provides information on highlighted stocks via press releases, newsletters and company website, but this should not be construed as a recommendation to buy or sell. Please visit the company website for a more complete list of risks and disclosures.